As a specialized holding entity with a primary emphasis on pharmaceutical development, clinical-stage drug candidates, and medical devices, Rafael Holdings competes within the broader biotechnology and healthcare sectors. Its peers include various small-cap and micro-cap biopharmaceutical companies focusing on rare diseases, oncology treatments, and specialized therapeutic research pipelines that vie for venture capital, clinical trial participants, and grant funding.